LifeMD, Inc. (LFMD) Stock

Understand LifeMD, Inc.: how it makes money

LifeMD connects consumers to telehealth doctors (concierge care, men's sexual health, dermatology, hair loss) and makes money through prescription dispensing, OTC products, and a medical device for hair loss. Revenue splits between its telehealth platform brands (ShapiroMD, RexMD) and WorkSimply, a staffing marketplace, with subscriber counts driving the recurring model.

LifeMD monetizes high-touch consumer health visits through high-margin product sales (prescriptions, OTC, a hair-loss device); the entire P&L is a function of how much each subscriber costs to acquire versus how much they spend per order.

Business quality (Weak): Weak. Revenue is shrinking, the company operates at a loss, and regulatory coverage in only 14 states limits near-term scale. The 89% gross margin is attractive on paper but is consumed by acquisition and overhead before reaching the bottom line.

Bull case

• CAC collapse drives breakeven path: Blended customer acquisition cost declined 70%, meaning each new subscriber costs far less to win. If the trajectory holds, the gap between recurring revenue and operating cost narrows quickly, moving the company toward sustainability.
• Women's health is a new engine: Women's health patient signups surged 657% quarter over quarter, indicating a second product category that can diversify revenue beyond the currently men's-health-weighted base and open additional prescribing opportunities.

Bear case

• Core revenue is shrinking: Revenue fell 24.6% year over year, showing the existing telehealth and product base is eroding rather than compounding. Without a clear offsetting growth line, top-line contraction compounds operating losses.
• Fourteen states is a small ceiling: The company holds licenses in only 14 states, capping the addressable market and making national scale (and the CAC leverage that comes with it) years away. Each new state is a regulatory hurdle that delays the unit-economics story.
• Still bleeding at the operating line: Operating margin stands at -15% despite an 89% gross margin, meaning marketing and overhead consume nearly all product-level profit. The structure is that of a funded growth company, not a self-sustaining one, and the -24.6% revenue trend offers no near-term relief.

Related Companies (Healthcare Services; 8 comparable companies)

• SBC Medical Group Holdings Incorporated (SBC)
• AirSculpt Technologies, Inc. (AIRS)
• The Oncology Institute, Inc. (TOI)
• Strata Critical Medical, Inc. (SRTA)
• Talkspace, Inc. (TALK)
• Park Dental Partners, Inc. Common Stock (PARK)
• Omada Health (OMDA)
• Viemed Healthcare, Inc. (VMD)